APOTEX has announced the approval of its ANDA No. 213331 from the FDA, marking the launch of the generic version of the substance and signaling a new competitive entry into the market. This regulatory clearance is expected to draw significant market share from the branded equivalent, triggering price erosion and impacting the revenue streams of competitors.